Icon

TECFIDERA (nda204063)- (120MG,240MG)

DIMETHYL FUMARATE BIOGEN INC
120MG,240MG
Yes No
2035-Nov-16 2018-Mar-27
None None
None No
TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
14 3 12
Total Other Developers 6
Drugs with Suitability No
120MG ** ** - - -
240MG ** ** Down 8 3
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ******** ******* ******* *** *********** **. **. ***/*, ********* (*******), *********(******), ******* *********** ********, ********* ******, ***** (***) ***
****** ***** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** ****** *** ***************, ***. ******* ***** *********** *-*, ******* *** **., ******* ****, ******, ****** (***) ***
****** *** ****** *** ***************, ***. ******* ***** ******** ** *********** **, ******** **.,, ******* ****, ******, ****** (***) ***
****** ****** ****** *************** ******* ******* *********** ***/*-***, ******* ****** **** ***** *********, *****, *********, ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ********* ****** ******** ****** ******* ******* *** *********** ****-**, **.**'*.**,**,**,**,** ** **,***&***, ************** * & **.** *,*,****,**,**,**,**&**, ************ *, *********** ******, **********, ****** ******* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.